Certara Software (CERT): Forward Price-to-Revenue Multiple

Public company logo of Certara, Inc. (CERT)

Certara, Inc. (CERT) relies on the indispensability of its software for pharmaceutical giants seeking regulatory approvals. The forward P/S history reflects market expectations, with the metric holding around 4.60. Market capitalization growth is supported by cloud SaaS solutions and FDA backing, while the active development of biosimulation products significantly reduces the costs and timelines of clinical trials.

Certara - CERT Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for Certara Software (CERT)

- current price and projected stock value:
Stock Price Certara|CERT - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Valuation Certara Software|CERT - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Certara|CERT - Book Valuation of Business|Market Value to Book Value Ratio certara.com|CERT - Total Business Assets
- debt and solvency information:
Total Debt to Capital Certara, Inc.|CERT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Certara, Inc.|CERT - Company Total Debt Obligations|Debts to Book Capitalization Certara Software|CERT - Company Long-Term Liabilities|Company Short-Term Debts Certara|Quick Liquidity certara.com
- financial results and valuation multiples details:
CERT - Final Profit|Future Profit Certara, Inc.|CERT - Market Price to Net Income Ratio|Forward P/E Multiple Certara Corp|CERT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Certara Software|CERT - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Certara|CERT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months certara.com|CERT - Net earnings per share growth this year|Earnings growth forecast for next year Certara, Inc.
- sales volume and revenue indicators:
CERT - Company Total Revenue|Projected Sales Volume Certara|CERT - Market Cap to Revenue Ratio|Forward P/S Multiple Certara Software
Comprehensive company analysis:Certara CERT
Product sample of certara.com

Assessing the fundamental value of Certara, Inc. (CERT) requires an analysis of the ratio between current market capitalization and projected sales. This coefficient determines the cost of one dollar of expected revenue, reflecting market expectations for business growth rates. By analyzing the forward P/S trend, an investor can see how the market values the synergy between biosimulations and M&A transactions within the medtech software sector. Elevated indicator values signal that the asset is overbought and carries high risks during a correction.

Competitors of Certara, Inc. (CERT)

Forward P/S Multiple VEEV (Veeva)|Forward P/S Multiple Doximity Inc DOCS|HQY: Forward Price-to-Revenue Multiple|Forward Price to Sales WAY (Waystar Corp)|CRVL: Forward P/S Multiple|PRVA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Huron|Market Cap to Projected Revenue OMCL (Omnicell Inc)|Forward P/S Multiple GDRX|Forward Price-to-Revenue Multiple Schrodinger Corp SDGR|Phreesia, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio omadahealth.com (OMDA)|Evolent Health - Forward P/S Multiple|HealthStream Inc (HSTM) - Forward Price-to-Revenue Multiple|DH: Forward P/S Multiple|Market Cap to Future Revenue Ratio Consensus Corp (CCSI)|Price-to-Projected Revenue Ratio Agilon Health|ABSI: Forward Price to Sales|Forward Price-to-Revenue Multiple SY (So-Young International Inc.)|Price to Expected Revenue Ratio NRC|Forward P/S Multiple SPOK (Spok Corp)|Market Cap to Expected Sales Ratio OptimizeRx Inc. (OPRX)|TBRG: Forward Price-to-Revenue Multiple|simulations-plus.com - Price to Expected Revenue Ratio|SOPH (sophiagenetics.com) - Forward Price-to-Revenue Multiple|Health Catalyst Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio CareCloud Inc.|Forward Price-to-Revenue Multiple Research Solutions Inc. (RSSS)|Forward P/S Multiple DLHC|ONMD - Market Cap to Future Revenue Ratio|Forward P/S Multiple SCNX (Scienture)|HCTI: Market Cap to Projected Revenue|iSpecimen Corp - Forward P/S Multiple|Bullfrog AI Holdings (BFRG) - Forward Price-to-Revenue Multiple|WORX: Forward P/S Multiple|Market Cap to Future Revenue Ratio msprecovery.com (MSPR)|Price-to-Projected Revenue Ratio iCoreConnect, Inc.|MEDS: Forward Price to Sales|Forward Price-to-Revenue Multiple ORGS (Orgenesis Corp)|Price to Expected Revenue Ratio RCM|Forward P/S Multiple SHCR (Sharecare, Inc.)|Forward P/S Multiple streamlinehealth.net STRM|SYRA - Price-to-Projected Revenue Ratio|Forward Price to Sales AMEH (Apollo Medical Holdings)|MODN: Forward P/S Multiple|NextGen Healthcare Corp (NXGN) - Forward P/S Multiple